Objective: To evaluate long-term clinical outcomes in cT1c-T3a prostate cancer patients following delayed-combined androgen blockade therapy. Methods: From January 2001 to December 2004, 92 cT1c-T3a prostate cancer cases were enrolled. Medical castration and anti-androgen treatment were used sequentially as delayedcombined androgen blockade therapy. Time to prostate-specific antigen biochemical failure was estimated, and risk factors for prostate-specific antigen biochemical failure were evaluated. Results: The average patient age was 76.4 years (range, 59-91 years), the median observation period was 52.8 months (range, 26 -106.6 months) and the median pre-treatment prostate-specific antigen level was 14 ng/ml (range, 3.68 -492 ng/ml). The TNM classification distribution was as follows: T1c, n ¼ 27; T2a, n ¼ 39; T2b, n ¼ 20; and T3a, n ¼ 6. In the multivariate analysis, Gleason's score 8 (P , 0.05; hazard ratio, 3.02), prostate-specific antigen nadir .1.4 ng/ml (P ¼ 0.001; hazard ratio, 8.76) and a half-life of the prostate-specific antigen level .1.2 months (P , 0.005; hazard ratio, 6.3) during the initial 6 months of luteinizing hormone-releasing hormone agonist monotherapy were significant independent risk factors for prostate-specific antigen biochemical failure with luteinizing hormone-releasing hormone agonist monotherapy. The high-risk group, which had at least one of these three risk factors, had a shorter time to prostate-specific antigen biochemical failure than the lowrisk group, during luteinizing hormone-releasing hormone agonist monotherapy (P , 0.0001). For the total delayed-combined androgen blockade therapy observation period, the free-prostate-specific antigen biochemical failure rate was 88.3% at 5 years. Only a maintenance period following luteinizing hormone-releasing hormone agonist monotherapy (P , 0.005; hazard ratio, 16.8) was revealed to be a significant independent risk factor for prostate-specific antigen biochemical failure with total delayed-combined androgen blockade. Conclusions: The free-prostate-specific antigen biochemical failure rate of delayed-combined androgen blockade therapy in our study was as valuable as those in other androgen deprivation therapy of previous reports.
INTRODUCTION
Androgen deprivation therapy (ADT) for prostate cancer (PC) is classified into two groups-the first consisting of only medical or surgical castration, and the second consisting of both anti-androgen treatment and either medical or surgical castration, called combined androgen blockade therapy (CABT).
According to medical guidelines, surgical and medical castration are the recommended initial treatments for metastatic PC. However, in terms of the initiation of ADT, early initial-CABT is not strongly recommended, because it remains debatable whether the small advantage of initial-CABT is meaningful (1) . In other words, the benefits of an initial-CABT upon the survival of PC patients remain controversial, and a statistically significant benefit has been reported only in patients with metastatic disease (2) (3) (4) .
Another kind of ADT, deferred (5, 6) or delayed-CABT (7, 8) , consists of initial luteinizing hormone-releasing hormone agonist monotherapy (LH-RHaM), followed by the administration of a non-steroidal anti-androgen. This type of ADT has been discussed in papers that included cases with metastasis and lymph node invasion.
These other types of ADT were evaluated mainly in patients with advanced PC, not in those with less advanced disease. Thus, for patients in the early stages of PC, the role of primary ADT is uncertain.
In patients with localized PC (LPC) and locally advanced PC (LAPC), primary ADT was shown to provide the same survival of the age-matched control group (9) . Primary ADT may be a standard optional treatment for selected LPC and LAPC patients (10) .
In our previous study, we first evaluated the efficacy of delayed-CABT in patients with LPC or LAPC (11), and we continued to estimate the long-term benefits.
In this study, we addressed the optimal parameters for predicting prostate-specific antigen biochemical failure (PSABF) in delayed-CABT over the long term. This approach will provide an optimal classification to identify the cases that should be treated with delayed-CABT.
PATIENTS AND METHODS
The inclusion criteria and treatment strategy were explained in detail previously (7, 11) . Based on the TNM staging, pelvic enhanced abdominal magnetic resonance imaging revealed local invasion. The metastasis of systemic organ and lymph node was decided by systemic enhanced computed tomography and bone scintigraphy.
From January 2001 to December 2004, 92 PC patients classified into the cT1c, cT2 and cT3aN0M0 groups were enrolled in this prospective study. The institutional review board at each institution approved the study, and all patients gave their full informed consent.
In this trial, we used androgen deprivation agents, including sequential monthly or tri-monthly subcutaneous injection of the LH-RHa: leuprolide acetate (3.75 or 11.25 mg) or goserelin (3.6 or 10.8 mg) and the non-steroidal antiandrogen [bicalutamide: daily oral intake (80 mg)]. We called this treatment regimen 'delayed-CABT,' and this protocol consisted of two steps, as described below.
The PSA level was determined during treatment with LH-RHaM to see whether monthly PSA levels decreased to less than the cut-off PSA level (lower than 0.2 ng/ml). We defined the PSA nadir level to be a cut-off PSA level.
We decided two administration criteria with an antiandrogen drug.
First, if a cut-off PSA level could not be achieved, then the PSA nadir level was defined as the final PSA level during its decline (over 0.2 ng/ml) that was followed by three elevations, and the PSABF with LH-RHaM was decided. Then, we added an anti-androgen drug.
Second, when patients achieved a cut-off PSA level, we continued treatment with LH-RHa alone. When patients exhibited three consecutive PSA level elevations over 0.2 ng/ ml, PSABF with LH-RHaM was defined, and we added an anti-androgen drug to the drug regimen. Thereafter, we continued to check the PSA level routinely until PSABF with an anti-androgen drug based on the same definition of LH-RHaM. The period of PSABF with total delayed-CABT was between the starting with LH-RHa and PSABF with additional anti-androgen drug (Fig. 1) . The PSA halflife was calculated according to a previously reported method (12) .
STATISTICAL ANALYSIS
The primary endpoint of the study was PSABF. The secondary endpoints were cause-specific survival and overall survival.
The Kaplan -Meier method was utilized to evaluate the rate of PSABF, cause-specific survival and overall survival, during each period, and statistical differences were estimated with the log-rank test. Multivariate analysis was performed using a Cox proportional hazards regression model.
The threshold of PSA nadir (.1.4 ng/ml), initial PSA (.20 ng/ml), or half-life (.0.9 or .1.2 months) and observation period with LH-RHa (14 months) were determined according to the univariate P values.
A P value of ,0.05 was considered statistically significant. Statistical analyses were performed using SPSS version 20 (SPSS Japan, Tokyo, Japan).
RESULTS
This study consisted of 92 patients; the average age of all patients was 76.4 years (range, 59 -91 years). The median observation period was 52.8 months (range, 26 -106.6 months). The median pre-treatment PSA level was 14 ng/ml (range, 3.68 -492 ng/ml). The classification based on the TNM was as follows: distribution, T1c 27, T2a 39, T2b 20, Jpn J Clin Oncol 2012;42 (6) 535 T3a 6, N0 92, N1 0, M0 92, M1a 0, M1b 0 and M1c 0. Forty-five patients had a Gleason score of 6, 26 patients had a Gleason score of 7 and 21 patients had a Gleason score of 8. These classifications were decided by the central pathologist (Table 1) . During LH-RHaM, a Kaplan -Meier analysis estimated that the proportion of patients without PSABF was 91.9% after 1 year, 75.1% after 3 years and 62.4% after 5 years.
In the multivariate analysis, three significant independent risk factors affected PSABF with LH-RHaM, a Gleason score of 8 [P , 0.05; hazard ratio (HR), 3 .02], a PSA nadir of .1.4 ng/ml (P ¼ 0.001; HR, 8.76) and a PSA halflife with LH-RHaM in the initial 6 months of .1.2 months (P , 0.005; HR, 6.30). Other factors were not significantly related to PSABF (Table 2) .
Using three risk factors (a Gleason score of 8, a PSA nadir of .1.4 ng/ml and a PSA half-life with LH-RHaM in the initial 6 months of .1.2 months) for LH-RHaM, we classified the entire set of cases into two groups, consisting of a high-risk group with 1 of these three risk factors (51 cases) and a low-risk group with no risk factors (41 cases). The non-PSABF rate was estimated with the Kaplan -Meier method for the comparisons between the high-risk group and the low-risk group, during LH-RHaM. The non-PSABF rate of the low-risk group was 92.9% at 5 years. In contrast, the non-PSABF rate of the high-risk group was 37.6%, which was significantly lower than that of the low-risk group (log-rank, P , 0.0001; Fig. 2 ).
Anti-androgen treatment was initiated in the 31 patients, who achieved the criteria of administration with an antiandrogen drug. A total of four cases reached a PSA nadir level of ,0.2 ng/ml, while 27 cases were assigned to the group with a PSA nadir of .0.2 ng/ml. After anti-androgen drug administration, 10 cases were diagnosed as PSABF against the anti-androgen drug. A Kaplan -Meier analysis estimated that the proportion of patients without PSABF was 89.1% after 1 year, 77.1% after 3 years and 60.9% after 5 years.
During the total delayed-CABT, 61 cases were maintained with LH-RHaM without PSABF and 31 cases received the anti-androgen drug. The non-PSABF rate was 100% after 1 year, 92.6% after 3 years and 88.3% after 5 years, respectively (Fig. 3) .
In the multivariate analysis, the only significant independent risk factor for PSABF with total delayed-CABT was an observation period (14 months) treatment with the LH-RHa (P , 0.005; HR, 16.8) ( Table 3) .
During the observation period, one patient died from cancer-related illness, and nine patients died from cancerunrelated illness. The Kaplan -Meier analysis estimated that the proportions of cancer-specific survival and overall survival were 100 and 100% after 1 year, 100 and 91.3% after 3 years and 98 and 87.5% after 5 years, respectively.
DISCUSSION
There is insufficient information regarding ADT for patients with LPC or LAPC, especially with modified treatment options, including delayed-CABT. In this study, we first 
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Delayed-combined androgen blockade therapy evaluated the efficacy of delayed-CABT in patients with LPC or LAPC over the long term. In terms of comparisons related to the survival benefit, the cancer-specific survival rate with initial-CABT or LH-RHaM at 8 years was 95.3 or 80.5%, respectively, in a population that included 39% of T3 stage PC patients (13) . In another report, the cancer-specific survival rate with ADT that included both initial-CABT and LH-RHaM at 5 and 10 years was 91 and 78%, respectively, in a population that included 45% of T3 stage PC patients (14) . In our report, the cancerspecific survival rate with delayed-CABT was 98% at 5 years and was associated with only one cancer-related death, in a population that included 6.5% of T3 stage PC patients. These results are difficult to compare with those of previous reports due to different background characteristics of the population, especially those related to the T stage, but the survival rates in our study were as valuable as those in previous reports.
What is the predictor of response for any kind of ADT? Several parameters related to PSA were evaluated previously. The period to nadir PSA .6 months was a risk factor for poor response to ADT (13) . A PSA level of 4 ng/ml with ADT at 12 months was a poor risk factor in patients with advanced PC (15) . A half-life of PSA .1 month with ADT was a poor risk factor in patients with advanced PC (16) . A PSA nadir with LH-RHaM of 4.0 ng/ml was a risk factor in patients with advanced PC with delayed-CABT (8) .
Except for the one paper that discussed the PSA half-life (16), the PSA nadir may be a crucial predictor during PSA analysis. However, it may take a long time to determine the PSA nadir, since the PSA nadir cannot be determined until the PSA level reaches the bottom. Consequently, it is possible to miss the optimal timing to initiate therapy with an anti-androgen drug for poor responders to ADT.
Based on these aspects, we continued to focus on the PSA half-life associated with the PSA nadir level in previous papers that included patients with advanced PC (7) or patients with LPC with LAPC (11). The PSA nadir was the optimal predictor in both reports, but the PSA half-life between the initial PSA level and the PSA level nadir with delayed-CABT, was not a significant risk factor in LPC with LAPC (11) .
In this study, we evaluated the PSA half-life in different periods after delayed-CABT. We found that the PSA half-life Jpn J Clin Oncol 2012;42(6) 537
with LH-RHaM in the initial 6 months of .1.2 months was a significant risk factor for PSABF, but not for the PSA halflife with LH-RHaM in the initial 3 months of .0.9 month. Since PSA flare-up with LH-RHaM affected the PSA halflife in the initial 3 months more than that in the initial 6 months, the PSA half-life in the initial 6 months could predict PSABF with LH-RHaM.
In our study, we determined that a maintenance period after LH-RHaM was the only predictor of progression on total delayed-CABT (Table 3) . Thus, it is indispensable to predict the likelihood of a maintenance period with LH-RHaM during delayed-CABT.
Can we predict progression in cases with shorter maintenance periods after LH-RHaM? According to the results of this study, cases with one or more of three risk factors (Gleason's sum 8, PSA half-life with LH-RHaM in the initial 6 months .1.2 months, and PSA nadir with LH-RHaM .1.4 ng/ml) had a high incidence of PSABF (Fig. 2) . Based on these risk factors, we established an algorithm to assess cases with shorter maintenance periods after LH-RHaM, as decided by sequential monitoring of these risk factors (Fig. 4) .
At the first checkpoint, as a pre-treatment parameter, since a Gleason sum of 8 was a significant risk factor for PSABF for LH-RHaM, cases with a Gleason sum of 7 may be optimal candidates for LH-RHaM among patients with LPC and LAPC. At the second checkpoint, after administration of LH-RHaM, a PSA half-life with LH-RHaM in 
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Delayed-combined androgen blockade therapy the initial 6 months of .1.2 months will be adapted. At the third checkpoint, a PSA nadir with LH-RHaM of .1.4 ng/ ml should be evaluated.
With this algorithm, we may identify the patients who would perform poorly on LH-RHaM sequentially, and thereby provide them with an opportunity to take an antiandrogen drug at an earlier time point. In addition, we will be able to select optimal candidates for initial LH-RHaM with the expectation of better control with LH-RHaM.
What is the benefit of sequential monitoring LH-RHaM? Since initial-CABT reduced patient quality of life (QOL) compared with LH-RHaM (2,17), LH-RHaM may provide QOL benefits. Delayed-CABT under the sequential monitoring LH-RHaM will prolong the period of LH-RHaM in the optimal cases and timing.
In this study, there were some limitations due to the single-arm protocol, without a comparator arm. However, we emphasized that LH-RHaM could maintain 62.4% of the cases during 5 years without an anti-androgen drug, and also delayed-CABT could maintain 88.3% of the cases after 5 years, comparable with initial-CABT. In the future, the efficacy of the delayed-CABT under this algorithm should be evaluated and compared with initial-CABT.
CONCLUSION
We could first report the efficacy of delayed-CABT in LPC and LAPC. The free-PSABF rate of delayed-CABT in our study was as valuable as those in other ADT of previous reports. We established an algorithm to select worse control of LH-RHaM. The worse control with LH-RHaM may be a contraindication for delayed-CABT. In the future, we must evaluate the efficacy of delayed-CABT, focusing on several aspects, including survival benefit, QOL and cost effectiveness. 
